Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced that it will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024, at 7:30 a.m. Central Time. Investors and interested parties can participate in the call by pre-registering through the provided link. The call will also be webcast and accessible through Baxter's website. It's important to note that the conference call will be recorded by Baxter and is copyrighted material, which cannot be recorded or rebroadcast without Baxter's permission.
Baxter International (NYSE:BAX), a global medtech leader, has announced a quarterly cash dividend of $0.29 per share of common stock. The dividend will be payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. This declaration sets the indicated annual dividend rate at $1.16 per share of common stock. This announcement demonstrates Baxter's commitment to providing regular returns to its shareholders, which may be seen as a positive sign of the company's financial stability and confidence in its future performance.
Baxter published its 2023 Corporate Responsibility Report, emphasizing its continued commitment to global healthcare, transparency, and environmental, social, and governance (ESG) topics. The report updates Baxter's progress toward its 2030 Corporate Responsibility Commitment and Goals, highlighting key achievements such as investing over $143 million since 2021 in underserved communities, partnering with UNICEF for climate-smart projects in Egypt, and completing 150 energy conservation projects that will reduce GHG emissions by 21,100 metric tons annually from 2024. Baxter also continues to excel in workplace safety and has enhanced its reporting by adopting the TCFD framework. The company plans to conduct a double materiality assessment to align its goals with evolving corporate responsibility standards, especially in light of the proposed separation of its Kidney Care business.
Baxter, a global leader in medical technology, announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for June 12, 2024, at 8:40 a.m. Eastern Time. Baxter's CFO, Joel Grade, will represent the company, providing insights into its financial position and future directions. The presentation will be available via live webcast on Baxter's official website and can be replayed through December 9, 2024.
Baxter announced that its expanded hemodialysis (HDx) therapy, enabled by the Theranova dialyzer, has shown to reduce all-cause mortality by approximately 25% over four years compared to high-flux hemodialysis (HF HD). The findings come from a cohort study involving 1,092 dialysis patients in Colombia, presented at the ERA-EDTA Congress. Of these, 533 patients received HF HD, while 559 received HDx therapy. The study emphasized HDx therapy's efficiency in removing large-middle molecule uremic toxins, linked to inflammation and cardiovascular issues in dialysis patients. HDx therapy uses the MCO membrane for better filtration and is compatible with existing HD machines, simplifying its implementation in clinics. Over 14 million HDx treatments have been conducted worldwide.
Baxter International (NYSE:BAX), a leading medtech company, is set to present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024.
The presentation will be led by Joel Grade, Baxter's CFO, at 9:30 a.m. Eastern Time.
The event will be webcast live and accessible via Baxter's website, with a replay available until December 2, 2024.
Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, Vantive. The mission, "Extending Lives, Expanding Possibilities," will guide Vantive in developing solutions for acute and chronic kidney diseases. The new logo, featuring a "V" motif in plum color, symbolizes the company's commitment to innovative therapies, digital solutions, and advanced services.
Vantive will build upon Baxter's nearly 70-year legacy in kidney care, aiming to improve outcomes for over one million patients annually across more than 70 countries. The separation of Vantive from Baxter's Renal Care and Acute Therapies businesses is expected to occur in the second half of 2024, either through a private equity sale or a public spinoff.
Baxter International Inc. (NYSE:BAX) has received FDA approval for an expanded indication for Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid provides essential fatty acids and calories for parenteral nutrition when oral or enteral nutrition is not possible. The approval highlights Baxter's commitment to meeting the nutritional needs of patients of all ages.
Baxter International Inc. (NYSE:BAX) will present at the Bank of America 2024 Health Care Conference with its chief financial officer, Joel Grade, scheduled to speak on May 15, 2024. The live webcast will be available for replay until August 14, 2024. Baxter is a global medtech leader offering a variety of healthcare products and solutions across the world.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share of common stock, with an indicated annual dividend rate of $1.16 per share. The dividend will be payable on July 1, 2024, to stockholders of record as of May 31, 2024.
FAQ
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
